

Original Article



Young Israeli women with epithelial ovarian cancer: prevalence of *BRCA* mutations and clinical correlates

Limor Helpman ^{1,2} Omri Zidan ² Eitan Friedman ^{2,3} Sarit Kalfon ²
Tamar Perri ^{1,2} Gilad Ben-Baruch ^{1,2} Jacob Korach ^{1,2}

¹Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel

²Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

³The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Israel



Received: Jan 31, 2017

Revised: Mar 31, 2017

Accepted: May 17, 2017

Correspondence to

Limor Helpman

Division of Gynecologic Oncology, Juravinski
Cancer Center, Hamilton Health Sciences,
699 Concession Street, Hamilton, ON L8V 5C2
Canada.

E-mail: thelpman@gmail.com

Copyright © 2017. Asian Society of
Gynecologic Oncology, Korean Society of
Gynecologic Oncology

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

ORCID iDs

Limor Helpman 

<https://orcid.org/0000-0002-3044-7247>

Omri Zidan 


<https://orcid.org/0000-0002-7721-7123>

Eitan Friedman 


<https://orcid.org/0000-0002-6745-1733>

Sarit Kalfon 


<https://orcid.org/0000-0002-6337-3651>

Tamar Perri 

<https://orcid.org/0000-0002-4042-6554>

Gilad Ben-Baruch 

<https://orcid.org/0000-0003-0270-3415>

Jacob Korach 

<https://orcid.org/0000-0003-0483-4582>

ABSTRACT

Objective: The current study investigates disease patterns and outcomes in young Israeli epithelial ovarian cancer (EOC) patients and their association with *BRCA* mutation status.

Methods: Consecutive EOC patients diagnosed at or below 50 years in a single institution between 1995–2011 were identified. All patients are referred for genetic counseling and testing for the predominant Jewish *BRCA* mutations: *BRCA1*-185delAG, *BRCA1*-5382insC, and *BRCA2*-6174delT. A comparison between *BRCA* mutation carriers and non-carriers was undertaken across demographic, pathologic, and clinical features; recurrence and survival were compared using the Kaplan-Meier method and associations with the variables of interest were analyzed using the Cox proportional hazards method.

Results: One hundred eighty-six patients diagnosed with EOC at 50 years or younger were included, with a total follow-up of 1,088 person years. Mean age at diagnosis was 44±5 years. Of 113 patients with documented *BRCA* testing, 49.6% carried a germline *BRCA* mutation, compared with 29% in the general Israeli EOC population ($p=0.001$). *BRCA* mutation carriers had a higher rate of serous tumors (75% vs. 64%, $p=0.040$) and higher CA125 levels at diagnosis (median, 401 vs. 157, $p=0.001$) than non-carriers. No significant association between *BRCA* mutations and recurrence (hazard ratio [HR]=1.03; $p=0.940$) or survival (HR=1.40; $p=0.390$) was found.

Conclusion: *BRCA* mutations are encountered in almost 50% of young Israeli ovarian cancer patients; they are associated with serous tumors and high CA125 levels at diagnosis, but are not independently associated with recurrence or survival in this patient population.

Keywords: *BRCA1*; *BRCA2*; Glandular and Epithelial Neoplasms; Ovarian Neoplasms; Young Adult; Women

INTRODUCTION

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer [1]. EOC is predominantly a post-menopausal disease, most frequently diagnosed in women in their sixties [1]. Of the known risk factors for developing EOC, family history of ovarian cancer plays a dominant role. Notably, in a substantial proportion of families with clustering of EOC, germline mutations in either the *BRCA1* or *BRCA2* genes are encountered [2].

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

This research was presented at the 2016 Annual Meeting on Women's Cancer, San Diego, USA, March 19–22, 2016.

Author Contributions

Conceptualization: H.L., F.E., K.J.; Data curation: H.L., Z.O., K.S.; Formal analysis: H.L., Z.O., P.T.; Investigation: H.L., Z.O., K.S.; Methodology: H.L., F.E.; Project administration: H.L.; Resources: F.E., B.B.G., K.J.; Supervision: H.L., F.E.; Validation: H.L.; Visualization: F.E., P.T., B.B.G., K.J.; Writing - original draft: H.L.; Writing - review & editing: H.L., F.E., P.T., B.B.G., K.J.

The spectrum of germline mutations in both genes amongst Jewish individuals, primarily but not exclusively of Ashkenazi origin, is limited: there are 2 *BRCA1* mutations (185delAG and 5382InsC) and one in the *BRCA2* mutation (6174delT) that are referred to as “founder Jewish *BRCA* mutations” [3–5]. The prevalence of these 3 predominant mutations has been reported in the general cancer-free Ashkenazi population (2.5%) [3], in unselected breast cancer cases (11%–12%) [6] and in unselected Israeli EOC cases (29%) [5]. 185delAG is also considered a founder mutation in Jewish individuals of Iraqi descent, in whom its prevalence in the general population is 0.5%.

The impact that *BRCA* gene mutations have on disease course, therapeutic response and overall survival (OS) in EOC is controversial. Most studies report an improved survival and better response to platinum based therapy among *BRCA* mutation carriers compared with non-carriers [4,7–13], but others have shown that long-term survival is independent of *BRCA* status [14]. Notably, these data were published prior to the recent addition of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors to the arsenal of therapeutic tools in EOC patients who carry a germline or a somatic *BRCA* mutation [15].

Diagnosing EOC under 50 years of age is uncommon, and may increase the likelihood of identifying an inherited predisposition [2]. *BRCA* mutations are more prevalent in young EOC patients [9,16]. There is a paucity of data on the effect of young age at EOC diagnosis on disease course and outcome, as well as on the impact of *BRCA* mutations on prognosis in young EOC patients. The current study was undertaken to address these questions, taking advantage of the unique preponderance of *BRCA* mutations in the Jewish Israeli population.

MATERIALS AND METHODS

1. Patient population

Consecutive patients diagnosed with EOC, fallopian tube cancer, or primary peritoneal cancer at or under 50 years and treated at the Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel between 1995 and 2011 were identified. Since 1996, all EOC patients at our institution are referred for genetic counseling and genotyping for the predominant Jewish *BRCA* mutations after completion of initial evaluation and treatment, usually during adjuvant chemotherapy. A large proportion are counseled and genotyped at the Oncogenetics Unit in the Sheba Medical Center.

2. Data collection

After obtaining institutional review board (IRB) ethical approval, medical records were reviewed and cross-referenced with databases at the Oncogenetics Unit to retrieve demographic and clinical data including patients' age at diagnosis, ethnicity, detailed family history of cancer, *BRCA* mutation status, medical and surgical history, disease stage and histology, CA125 levels at diagnosis and surgical outcome. Additionally, follow-up data on disease course including surgical outcome, chemotherapy, disease recurrence and re-treatment, follow-up and survival data were collected. Disease-free survival (DFS) was calculated from the completion of adjuvant chemotherapy to the date of first recurrence or last follow-up. OS was calculated from diagnosis to death, or last follow-up.

3. Statistical analysis

The prevalence of *BRCA* mutations in the study population, was extracted and compared with historical data available for the general Israeli EOC patient population [5]. A comparative

analysis was performed between *BRCA* mutation carriers and non-carriers among study participants, across demographic, pathological, and clinical features. Survival data were compared using the Kaplan-Meier method and the log-rank test. The associations of clinical, genetic, pathological, and surgical variables with DFS and OS were assessed using the Cox proportional hazards method. Statistical analysis was performed on SPSS software (SPSS version 23; IBM Corp., Armonk, NY, USA).

4. Genetic testing

BRCA genotyping encompassed the 3 predominant Jewish Ashkenazi mutations in all cases, as previously described [17]. Since 2010 a NanoChip™ technology that genotypes for predominant and recurring *BRCA* mutations was applied [18]. All mutations were confirmed by sequencing. Genetic mutation testing is covered under the national health act and is performed free of charge for all women with the diagnosis of EOC.

Patients who tested negative for specific germline mutations were counseled about the possibility of harboring a private *BRCA* mutation and the availability of *BRCA* sequencing and extended genetic workup. Sequencing of *BRCA* was added to the public health coverage in 2012. Other extended testing, including multigene panel testing, is not covered and can be funded under private and supplementary health insurances.

RESULTS

Of 196 patients diagnosed with EOC at 50 years or younger and treated at the Sheba Medical Center during the study period, 186 records were found to have sufficiently complete data to be included in this analysis. Median length of follow-up (to last visit or date deceased) was 52 months (interquartile range, 31–92 months). Patients were 25–50 years old at diagnosis (mean, 44±5 years). Three patients (1.6%) were diagnosed under 30 years of age; 29 patients (15.6%) were 30–39 years old at diagnosis; and the majority (154, 83%) were in their forties.

The overwhelming majority of patients (162 patients—87.1% of the cohort) were Jewish, representing almost all patients in whom ethnicity was documented in the medical record. Only 2 Israeli Arabs were identified in this study population; for 22 patients no information on ethnicity was available on record. Of 104 patients for whom parental ethnicity was known, most were of Ashkenazi (n=48) or mixed Ashkenazi (n=10) descent—56% of the total. Thirty-eight patients (37%) were of non-Ashkenazi Jewish descent, including Balkan, North African and Asian (Iraqi, Iranian), or Yemenite descent.

Six patients had been diagnosed with breast cancer prior to EOC diagnosis. One hundred ten (59.1%) had family history of cancer in at least 1 or 2 first/second-degree relatives: breast cancer in 36 patients and ovarian cancer in 20 patients.

BRCA mutation status was unknown for 73 patients. Of 113 patients with known genetic testing results, 57 patients were *BRCA* mutation carriers (49.6%); this included 53 *BRCA1* mutation carriers, 3 *BRCA2* mutation carriers and 1 patient who carried mutations in both *BRCA* genes. Among *BRCA1* mutation carriers, the most prevalent was the 185delAG mutation, identified in 32 patients (60%). There were also 6 5382insC mutation carriers and 4 Tyr978X mutations carriers. Eleven mutations identified were private *BRCA1* mutations (a genetic mutation found only in a single family, as opposed to recurring or founder mutations which are found

in unrelated families within a certain population and originate in a common ancestor). Six mutations were found in women under 39 years of age; 23 mutations in 40–44 years old patients and the rest were diagnosed in women 45–50 years of age. Binomial test showed a statistically significant difference when comparing the prevalence of *BRCA* mutations in the present study population, with data published for the general Israeli EOC population (29%, $p < 0.001$).

BRCA mutation carriers had a higher prevalence of familial cancer history (84% vs. 61% in non-carriers, $p = 0.050$). Specifically, a higher prevalence of breast and ovarian family cancer history was documented in *BRCA* mutation carriers compared with non-carriers (63% vs. 18%, $p < 0.010$).

The majority of EOC in the study population were of serous histology (126, 68%); other cell types included endometrioid (24, 13%), mucinous (7, 4%), and clear cell (13, 7%) histologies. Of note, *BRCA* mutation carriers were more likely to have a serous tumor whereas non-serous histologies and specifically, clear cell tumors were more frequently represented among non-carriers (**Table 1**).

In this young EOC population, 35% of patients were diagnosed at early stages (I–II) and 65% were diagnosed at advanced stages (III–IV). Although not statistically significant, stage distribution was skewed in favor of advanced disease in *BRCA* mutation carriers (64% vs. 52%, $p = 0.250$); this was also reflected in higher CA125 levels at diagnosis when both groups are compared (**Table 1** and **Fig. 1**).

Over the course of their disease, patients received a mean of 3 lines of chemotherapy (0–12, standard deviation [SD]=2.7). Most patients recurred or had persistent disease (108 and 7 patients, respectively), but 71 patients (38%) remained disease-free over the entire follow-up

Table 1. Patient and disease characteristics in *BRCA* mutation carriers and non-carriers

Characteristics	<i>BRCA</i> mutation carriers (n=57)	<i>BRCA</i> non-carriers (n=56)	Total population (n=186)	p-value (carriers vs. non-carriers)
Age (mean)	45.0±4.6	43.3±6.1	44.1±5.2	NS
Ashkenazi Jewish descent	23 (40.4)	16 (28.6)	58 (56)	0.236
Family history of cancer	48 (84.2)	34 (60.7)	110 (62.9)	0.006
Family history of breast/ovarian cancer	36 (63.2)	10 (17.9)	59 (33.7)	<0.001
First menstrual period (mean age)	12.8	12.8	13.0	NS
Gestations (mean)	3.5	2.9	3.1	NS
Deliveries (mean)	2.4	1.8	2.0	NS
Histology*				0.043 [†]
Serous	43 (75)	36 (64)	126 (68)	
Mucinous	2 (4)	2 (4)	7 (4)	
Endometrioid	5 (9)	6 (11)	24 (13)	
Clear cell	0	8 (14)	13 (7)	
Stage diagnosed				0.250 [‡]
I	11 (20)	20 (37)	43 (23)	
II	9 (16)	6 (11)	21 (11)	
III	32 (58)	26 (48)	103 (55)	
IV	3 (6)	2 (4)	14 (8)	
CA125 level at diagnosis	401 (122–1,100)	157 (39–415)	314 (80–875)	0.001 [§]
No residual tumor at surgery [¶]	35 (74.5)	32 (71.1)	98 (67.1)	0.877

Values are presented as number (%) or median (interquartile range). Most patients tested for 3 founder mutations: *BRCA1*-185delAG, *BRCA1*-5382insC, and *BRCA2*-6174delT.

*Other histologies included undifferentiated, anaplastic, mixed, and Brenner cell tumors; [†]p-value for serous vs. other (mucinous, endometrioid, and clear cell tumors); [‡]p-value for early (stage I–II) vs. advanced (stage III–IV) disease; [§]p value for lnCA125 (plotted logarithmically due to extreme outliers); [¶]Of 146 patients for whom residual tumor information was available.

NS, not significant.




Fig. 1. CA125 levels in *BRCA* mutation carriers vs. non-carriers. CA125 levels in *BRCA* mutation carriers were significantly higher at diagnosis (median, 401 vs. 157; $p=0.001$) and had a wider interquartile range (122–1,100 vs. 39–415).

period. Twenty-nine of these were *BRCA* mutation carriers, 27 were non-carriers, and the rest had unknown *BRCA* mutation status.

Five-year OS was 68% for *BRCA* mutation carriers and 65% for non-carriers ($p=0.800$). Univariate analyses showed early disease stage, maximal cytoreduction to no residual disease and non-serous histology were significantly associated with improved DFS and OS; however, *BRCA* mutations did not impact disease outcome (**Fig. 2**). Fifty patients with advanced (stage III–IV), high grade serous or endometrioid cancers with known *BRCA* mutation status were identified within the patient population. For this subgroup, as well, no significant association between *BRCA* mutations and either DFS or OS was found (**Fig. 3**).




Fig. 2. DFS (A) and OS (B) in *BRCA* mutation carriers vs. non-carriers. Median DFS was 46.2 months for non-carriers and 73.4 months for *BRCA* mutation carriers ($p=0.910$); median OS was not reached for non-carriers and was 213.7 months for *BRCA* mutation carriers ($p=0.730$). DFS, disease-free survival; OS, overall survival.




Fig. 3. DFS (A) and OS (B) in advanced, high-grade serous, and endometrioid ovarian cancer: *BRCA* mutation carriers vs. non-carriers. Disease outcome in a subpopulation of patients with advanced (stage III–IV), high-grade serous, or endometrioid ovarian tumors. Median DFS was 20.9 months for non-carriers and 21.2 months for *BRCA* mutation carriers ($p=0.220$); median OS was 63.5 months for non-carriers and 71.9 months for *BRCA* mutation carriers ($p=0.720$). DFS, disease-free survival; OS, overall survival.

Table 2. HR for recurrence and death (Cox proportional hazards method)

Characteristics	Recurrence		Death	
	HR	p-value	HR	p-value
<i>BRCA</i> mutation	1.03 (0.56–1.88)	0.940	1.40 (0.65–2.99)	0.390
Non-serous histology	0.80 (0.36–1.75)	0.570	0.93 (0.30–2.83)	0.890
Advanced stage (III–IV)	1.29 (0.56–2.94)	0.550	1.40 (0.46–4.30)	0.560
Residual tumor at surgery (reference, no macroscopic disease)	3.02 (1.39–6.57)	0.005	2.31 (0.90–5.91)	0.080

HR, hazard ratio.

Multivariable analysis was confounded by an association of early disease stage and non-serous histology with lower residual disease at surgery ($p<0.001$, Chi-squared test). When residual disease at surgery was excluded from the analysis, multivariable Cox proportional hazards modeling demonstrated a significant association of both stage and histology with OS with a hazard ratio (HR) for death of 0.58 for non-serous histology ($p=0.038$) and 3.66 for advanced stage ($p<0.001$). However, in an analysis incorporating all variables, residual disease at surgery was independently associated with recurrence ($HR=3$; $p=0.005$) and non-significantly associated with survival ($HR=2.3$ for death, $p=0.080$) whereas other variables lost their association with outcome (**Table 2**). *BRCA* mutation status, which was not associated with residual disease at surgery ($p=0.880$), was not found to be independently associated with recurrence or survival in either analysis.

DISCUSSION

This retrospective cohort study focuses on an under-researched patient population: young women with EOC. Patients were selected for diagnosis at age 50 and below, with a mean age

of 44. The patient population described in the study is also unique in its ethnic composition. Being set in the major urban center of Israel, the vast majority of patients are Jewish, and specifically Jewish Ashkenazi.

Nearly half of the current study participants with known genetic testing results harbored a germline *BRCA* mutation. This is higher than the rate reported for consecutive ovarian cancer cases in most other studies, ranging from 10% to 20% across different populations [19-21]. It is notably also higher than the 29% prevalence reported for an Israeli ovarian cancer patient population who were unselected for age or family history of cancer [5] or the 25%–40% reported for other Jewish ovarian cancer patient cohorts [16,22,23]. These studies are summarized in a review analyzing *BRCA* mutations in Korean ovarian cancer patients [24]. The co-occurrence of 2 risk factors, young age and Jewish ethnicity, combine here to account for an exceptionally high rate of *BRCA* mutations. *BRCA2* mutations were infrequent in this young ovarian cancer patient population, which is consistent with the older age at cancer diagnosis reported for *BRCA2* mutation carriers in multiple studies [16,25,26].

In the present study cohort, the majority (63%) of young EOC patients had a family history of cancer, and a substantial proportion had a family history of breast and/or ovarian cancer (34%), with notably higher rates of cancer history amongst families of *BRCA* mutation carriers (**Table 1**). It is well accepted that family history impacts on an individual's risk of cancer, a paradigm applicable to both individuals with and without identifiable mutations [27,28]. The Hereditary Breast Cancer Clinical Study Group has previously shown a 1.2 (breast)–1.6 (ovary)-fold increase in cancer risk above baseline in *BRCA* mutation carriers for each first degree relative with cancer diagnosed under the age of 50 [29]. A family history of cancer also impacts on the age at diagnosis of *BRCA*-related cancers, with cancer diagnosed 8 years earlier in subsequent generations [30]. These observations are important in providing guidance for the timing of surveillance initiation and of risk reducing interventions in diagnosed *BRCA* mutation carriers as well as in high-risk women without an established genetic diagnosis. Of note, over one third of *BRCA* carriers in this study had no family history of breast or ovarian cancer, highlighting the need for genetic counseling and testing in all EOC in Israel, and specifically in those diagnosed by age 50 years, regardless of family history.

Over one third of the patients included in this study had no report of *BRCA* testing in their medical record despite a policy of 100% referral and full coverage of counseling and testing under the national health act. This, coupled with the high prevalence of *BRCA* mutations in the Israeli ovarian cancer population and particularly in the Jewish Ashkenazi population, highlights the importance of proactive counseling by providers on the importance of genetic testing. A low uptake of genetic testing for *BRCA* mutations has been reported by other groups [31-33] and has improved over time with better acceptance [34,35]. Uptake of genetic counseling and testing may be affected by various disease and patient characteristics [36-39]. Patients with rapidly progressive disease, for example, may have less opportunity to complete testing. Ethnic, cultural, and religious background may impact genetic counseling and testing acceptance; in Israel, orthodox patients are more likely to decline genetic testing as compared to secular ones, for *BRCA* as well as other diagnoses [40]. Low rates of uptake are often attributed to an overwhelming burden of information and competing tasks our patients and their supporters face [31,32]. Working hand in hand with the oncogenetics services to provide patients with a counseling appointment as soon as ovarian cancer is diagnosed is imperative, in order to improve compliance and ensure that the majority of patients fall in with the international guideline for genetic testing. Making a genetic diagnosis in EOC cases

is becoming increasingly important with PARP inhibitors taking the front stage in some treatment protocols and in many clinical trials.

BRCA mutation carriers showed a preponderance of high grade serous tumors; this histologic predilection is consistent with the literature [8]. Interestingly, histologic subtypes are distributed somewhat differently in the young EOC population studied herein than in the general ovarian cancer patient population [41], with a higher prevalence of non-serous histologies; this is particularly striking for non-mutation carriers, in whom clear cell histology—usually observed in under 3% of EOC—appears in 14% of cases (**Table 1**).

Outcomes for these young ovarian cancer patients were more favorable than reported for the general EOC population. Recurrence rate was only 57% for the study population over the course of follow-up, and median OS was 85 months. This may be partly explained by a more favorable stage distribution with 34% of patients diagnosed with stage I–II disease, as well as by a higher rate than usual of non-serous histologies (32%). Interestingly, *BRCA* mutation status did not have an independent impact on DFS or OS on either univariate or multivariate analysis (**Fig. 2** and **Table 2**), contrary to previous reports suggesting *BRCA* mutation carriers may have better outcome compared to non-carriers [9-13]. The higher prevalence of early, non-serous tumors among non-*BRCA* carriers in this selected population may partly account for these results; in fact, Cox proportional hazards analysis pointed to histology and stage as stronger predictors of survival than *BRCA* status, as was residual macroscopic disease at surgery (**Table 2**). With this in mind, we looked at a subgroup of patients with advanced, high-grade serous, and endometrioid disease more representative of the typical ovarian cancer patient population; this was a small group consisting of only 50 patients, but again, no association between *BRCA* mutation and outcome was identified (**Fig. 3**). Our findings are in line with some reports on long-term survival in EOC patients, discounting an association with *BRCA* mutations [14,42].

This study has several important limitations. As a retrospective cohort study, it has inherent flaws including access to important information that may be missing from medical records, loss to follow-up and widely varying follow-up periods impacting OS analysis. The study was conducted at a major tertiary gynecological cancer center, which has a broad referral base and is also public and accessible to all; however, it is ultimately a single institution study, with potential impact on patient selection, as evidenced by an overwhelming majority of Jewish patients. *BRCA* testing was missing in over one third of study patients, introducing a possible bias; both disease and patient characteristics may impact on the uptake of genetic testing. Some of the variables impacting on disease outcome, such as non-serous histology, early disease stage, and no macroscopic residual disease are interdependent, confounding the multivariable analysis. Mutation carriers tended to have more advanced disease at presentation, possibly skewing recurrence and survival results. Finally, the subgroup of patients with advanced, high-grade serous, and endometrioid tumors where *BRCA* mutation status would potentially have more impact was too small to allow multivariate analyses.

Despite these limitations, this report does shed light on an under-studied population of young EOC patients. Our findings show the frequency of *BRCA* mutations in young Israeli ovarian cancer patients to be about 50%, highlight differences in histologic subtypes and in disease patterns between *BRCA* mutation carriers and non-carriers, and support the hypothesis that *BRCA* gene mutation status may not independently impact disease course or survival in this young EOC population.

REFERENCES

1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SE, et al. SEER cancer statistics review, 1975–2012. Bethesda, MD: National Cancer Institute; 2015.
2. Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, et al. Genetic/familial high-risk assessment: breast and ovarian, version 2.2015. *J Natl Compr Canc Netw* 2016;14:153-62.
[PUBMED](#) | [CROSSREF](#)
3. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common *BRCA1* and *BRCA2* mutations among Ashkenazi Jews. *Am J Hum Genet* 1999;64:963-70.
[PUBMED](#) | [CROSSREF](#)
4. Modan B, Gak E, Sade-Bruchim RB, Hirsh-Yechezkel G, Theodor L, Lubin F, et al. High frequency of *BRCA1* 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. *JAMA* 1996;276:1823-5.
[PUBMED](#) | [CROSSREF](#)
5. Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, et al. Population attributes affecting the prevalence of *BRCA* mutation carriers in epithelial ovarian cancer cases in Israel. *Gynecol Oncol* 2003;89:494-8.
[PUBMED](#) | [CROSSREF](#)
6. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the *BRCA1* and *BRCA2* genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 1998;62:676-89.
[PUBMED](#) | [CROSSREF](#)
7. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, et al. Effect of *BRCA* mutations on the length of survival in epithelial ovarian tumors. *J Clin Oncol* 2002;20:463-6.
[PUBMED](#) | [CROSSREF](#)
8. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between *BRCA1* and *BRCA2* mutations and survival in women with invasive epithelial ovarian cancer. *JAMA* 2012;307:382-90.
[PUBMED](#) | [CROSSREF](#)
9. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with *BRCA*-associated ovarian carcinoma. *Cancer* 2003;97:2187-95.
[PUBMED](#) | [CROSSREF](#)
10. Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J, et al. Prognostic impact of *BRCA1* pathogenic and *BRCA1/BRCA2* unclassified variant mutations in patients with ovarian carcinoma. *Cancer* 2005;104:1004-12.
[PUBMED](#) | [CROSSREF](#)
11. Safra T, Lai WC, Borgato L, Nicoletto MO, Berman T, Reich E, et al. *BRCA* mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups. *Ann Oncol* 2013;24 Suppl 8:viii63-8.
12. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with *BRCA1* and *BRCA2* mutations. *J Clin Oncol* 2008;26:5530-6.
[PUBMED](#) | [CROSSREF](#)
13. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. *BRCA* mutation frequency and patterns of treatment response in *BRCA* mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *J Clin Oncol* 2012;30:2654-63.
[PUBMED](#) | [CROSSREF](#)
14. Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, et al. Ten-year survival after epithelial ovarian cancer is not associated with *BRCA* mutation status. *Gynecol Oncol* 2016;140:42-7.
[PUBMED](#) | [CROSSREF](#)
15. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by *BRCA* status in a randomised phase 2 trial. *Lancet Oncol* 2014;15:852-61.
[PUBMED](#) | [CROSSREF](#)
16. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline *BRCA1* and *BRCA2* mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 2001;68:700-10.
[PUBMED](#) | [CROSSREF](#)
17. Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, et al. Mutational analyses of *BRCA1* and *BRCA2* in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. *Hum Mutat* 2000;16:491-501.
[PUBMED](#) | [CROSSREF](#)

18. Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L, et al. The rate of recurrent *BRCA1*, *BRCA2*, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. *Cancer Genet* 2016;209:50-2.
[PUBMED](#) | [CROSSREF](#)
19. Garber JE, Offit K. Hereditary cancer predisposition syndromes. *J Clin Oncol* 2005;23:276-92.
[PUBMED](#) | [CROSSREF](#)
20. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. *BRCA1* and *BRCA2* mutations account for a large proportion of ovarian carcinoma cases. *Cancer* 2005;104:2807-16.
[PUBMED](#) | [CROSSREF](#)
21. Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in *BRCA1*, *BRCA2* and the mismatch repair genes to ovarian cancer in the population. *Hum Mol Genet* 2014;23:4703-9.
[PUBMED](#) | [CROSSREF](#)
22. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, et al. *BRCA1* and *BRCA2* mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. *Am J Hum Genet* 2000;66:1259-72.
[PUBMED](#) | [CROSSREF](#)
23. Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR, et al. Founder *BRCA 1* and *2* mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. *Gynecol Oncol* 2000;78:148-51.
[PUBMED](#) | [CROSSREF](#)
24. Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK, et al. *BRCA1* and *BRCA2* germline mutations in Korean ovarian cancer patients. *J Cancer Res Clin Oncol* 2009;135:1593-9.
[PUBMED](#) | [CROSSREF](#)
25. Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, et al. Clinical characteristics and outcomes of *BRCA*-associated ovarian cancer: genotype and survival. *Cancer Genet* 2012;205:34-41.
[PUBMED](#) | [CROSSREF](#)
26. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al. Characterization of *BRCA1* and *BRCA2* mutations in a large United States sample. *J Clin Oncol* 2006;24:863-71.
[PUBMED](#) | [CROSSREF](#)
27. Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, et al. Familial clustering of site-specific cancer risks associated with *BRCA1* and *BRCA2* mutations in the Ashkenazi Jewish population. *Proc Natl Acad Sci U S A* 2006;103:3770-4.
[PUBMED](#) | [CROSSREF](#)
28. Antoniou AC, Pharoah PD, Easton DF, Evans DG. *BRCA1* and *BRCA2* cancer risks. *J Clin Oncol* 2006;24:3312-3.
[PUBMED](#) | [CROSSREF](#)
29. Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, et al. Family history of cancer and cancer risks in women with *BRCA1* or *BRCA2* mutations. *J Natl Cancer Inst* 2010;102:1874-8.
[PUBMED](#) | [CROSSREF](#)
30. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, et al. Earlier age of onset of *BRCA* mutation-related cancers in subsequent generations. *Cancer* 2012;118:321-5.
[PUBMED](#) | [CROSSREF](#)
31. Peters N, Domchek SM, Rose A, Polis R, Stopfer J, Armstrong K. Knowledge, attitudes, and utilization of *BRCA1/2* testing among women with early-onset breast cancer. *Genet Test* 2005;9:48-53.
[PUBMED](#) | [CROSSREF](#)
32. Petzel SV, Vogel RI, Benseid T, Leininger A, Argenta PA, Geller MA. Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic. *J Genet Couns* 2013;22:662-73.
[PUBMED](#) | [CROSSREF](#)
33. Rose AL, Peters N, Shea JA, Armstrong K. Attitudes and misconceptions about predictive genetic testing for cancer risk. *Community Genet* 2005;8:145-51.
[PUBMED](#)
34. Sussner KM, Edwards T, Villagra C, Rodriguez MC, Thompson HS, Jandorf L, et al. *BRCA* genetic counseling among at-risk Latinas in New York City: new beliefs shape new generation. *J Genet Couns* 2015;24:134-48.
[PUBMED](#) | [CROSSREF](#)
35. Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, et al. Lack of referral for genetic counseling and testing in *BRCA1/2* and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. *Breast Cancer Res Treat* 2013;141:135-44.
[PUBMED](#) | [CROSSREF](#)
36. Peters N, Rose A, Armstrong K. The association between race and attitudes about predictive genetic testing. *Cancer Epidemiol Biomarkers Prev* 2004;13:361-5.
[PUBMED](#)

37. Sanz J, Ramón y Cajal T, Torres A, Darder E, Gadea N, Velasco A, et al. Uptake of predictive testing among relatives of *BRCA1* and *BRCA2* families: a multicenter study in northeastern Spain. *Fam Cancer* 2010;9:297-304.
[PUBMED](#) | [CROSSREF](#)
38. Simon MS, Petrucelli N. Hereditary breast and ovarian cancer syndrome : the impact of race on uptake of genetic counseling and testing. *Methods Mol Biol* 2009;471:487-500.
[PUBMED](#) | [CROSSREF](#)
39. Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB. Barriers and facilitators to *BRCA* genetic counseling among at-risk Latinas in New York City. *Psychooncology* 2013;22:1594-604.
[PUBMED](#) | [CROSSREF](#)
40. Rose E, Schreiber-Agus N, Bajaj K, Klugman S, Goldwaser T. Challenges of pre- and post-test counseling for orthodox Jewish individuals in the premarital phase. *J Genet Couns* 2016;25:18-24.
[PUBMED](#) | [CROSSREF](#)
41. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. *Int J Gynecol Pathol* 2008;27:161-74.
[PUBMED](#)
42. Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, et al. Germline mutation in *BRCA1* or *BRCA2* and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clin Cancer Res* 2015;21:652-7.
[PUBMED](#) | [CROSSREF](#)